Artificial intelligence, once viewed as a distant promise within the pharmaceutical industry, has accelerated its way into operational reality.

Over the last few months advancements in generative models, autonomous agents, and data-driven automation have ignited a seismic shift spanning across drug development, clinical operations, and regulatory governance. These updates redefine how companies navigate discovery, design studies, manage data, and validate compliance.

Pharmaceutical Executive was able to speak with two industry leaders regarding the transformation of AI in the industry Darko Matovski, CEO of CausaLens, and Raj Indupuri, CEO of eClinical Solutions.

While Matovski emphasizes governance, explainability, and regulatory alignment as the prerequisites for AI’s safe adoption, Indupuri focuses on the operational pressures driving rapid integration of AI, such as unprecedented data volumes, rising protocol complexity, and the inefficiencies slowing clinical development.

Using trust as the cornerstone of AI adoption

A consistent concern among industry leaders surrounds the transparency of AI systems, specifically concerns regarding AI systems generating outputs without showing their work. Matovski touches on this lack of transparency, saying its incompatible with high-stakes decision-making in drug development.

“Pharma leaders are smart to worry about ‘black box’ AI,” Matovski said. “You can’t validate what you can’t see, regulators can’t audit it, trust disappears very quickly, and time-to-market is lengthened.”

To address this, companies such as CausaLens have engineered Digital Worker frameworks focused on providing full visibility, including tracible decisions, auditability, and independent judges for accuracy before finalization. Matovski describes the system as a “glass box, not a black box,” being designed to allow every action to be logged line-by-line, from “Judge Agents” evaluating safety, compliance, and correctness in real time.

For heavily regulated environments, where evidence chains must be able to withstand audits, inspections, and legal scrutiny, this level of interpretability is not a luxury, but is rather a prerequisite for adoption.

Transitioning compliance into speed

Compliance is often viewed as a bottleneck slowing development, yet Matovski contends that AI, if properly designed, can convert compliance from a reactive afterthought into a proactive accelerator.

“Digital Workers operate within regulated systems, automatically validating evidence and remaining fully observable,” he said. “Compliance becomes a continuous layer of assurance that accelerates approvals and reduces rework.”

By embedding governance directly into workflows in AI platforms AI has the potential to streamline documentation, minimize errors, and collapse review timelines. A shift of this scale holds the potential to fundamentally realign how pharmaceutical companies approach regulatory readiness, evolving it from a point-in-time exercise to a continuous automated function.

However, this evolution raises new ethical questions. As AI begins and continues to influence patient stratification and treatment personalization, transparency, safety, and data protection all become more critical. In his conversation with Pharmaceutical Executive, Matovski notes that regulators are “racing” to keep pace with AI’s rapid acceleration, with concerns around bias, interpretability, and appropriate levels of human oversight are expected to require continuous collaboration and clear frameworks moving forward.

How AI is reshaping clinical development?

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In his conversation with Pharmaceutical Executive Indupuri, touched on the fact that the volume of data generated in modern clinical trials has reached an inflection point that traditional systems can no longer manage.

“In 2012, a Phase III trial collected around 900,000 data points,” Indupuri said. “In 2025, that number is roughly 6 million. The amount of data we’re collecting is exploding.”

Along with the growth of data generation, study designs are also growing more ambitious despite patient recruitment remaining a challenge and cycle times continuing to grow in length. These factors have created several structural inefficiencies across the clinical development value chain, which are inefficiencies that AI is crafted to reduce.

“The promise of AI is eliminating manual inefficiencies and helping us get insights from this data quickly enough to act,” he explained. “If we embed AI across the value chain, cycle times can be reduced, risk can be reduced, and overall study costs can be drastically lowered.”

For Indupuri, the imperative is clear: without AI, the industry risks being overwhelmed by its own data.

Why scaling AI remains a challenge

Although the industry has seen massive investments into AI systems and models, many organizations remain stuck in pilot mode and are unable to scale AI across global operations. With both regulatory complexity and patient data sensitivity compounding these challenges, it creates a requirement for robust guardrails that many early AI tools lack.

Indupuri argues that pharma can overcome these barriers through embedding AI into previously existing deterministic workflows rather than replacing them. “We combine AI models with the automated, rule-based workflows we’ve built for over a decade,” he said. “If you can add AI as a layer, you create trust, and adoption follows.”

He believes the next two to three years will be a key turning point where requirements solidify themselves, while enabling organizations to not only expand capabilities but also surpass experimentation to enterprise-wide deployment.

Data infrastructure: the hidden foundation of reliable AI

In their respective conversations with Pharmaceutical Executive both leaders underscored the same truth, AI is only as strong as the data it learns from.

“Without data, there is no AI,” Indupuri said. “Strong data foundations are imperative.”

For eClinical, that translates to unifying patient data, governing it rigorously, and embedding AI only on top of validated, controlled datasets. As generative models make it easier than ever to build new tools “you don’t need to be a data scientist anymore,” Indupuri noted, the need for guardrails becomes even more urgent.

Industry best practices are beginning to center on the following:

• Unified data platforms
• Governance and lineage tracking
• Validated model performance
• Guardrails for responsible use
• Embedded privacy and security controls

AI’s potential is immense, but without disciplined data foundations, its insights are neither reliable nor actionable.

AI’s role in risk mitigation, study quality, and trial agility

With trials continuing to expand in both size and complexity, risk-based strategies are becoming essential. Indupuri touched on how he sees AI playing a decisive role in improving quality and accelerating decision-making across the lifecycle.

“If you don’t take risk-based strategies, it becomes very difficult to focus on quality,” he said. “The industry is moving toward approaches that evaluate criticality from the start, design, conduct, data review, everything.”

By pairing strong data infrastructure with AI-driven analytics, companies gain the ability to the following:

• Detect emerging issues earlier
• Prioritize review based on critical data
• Adjust protocols in real time
• Reduce costly delays
• Improve regulatory confidence

The promise is a future where trials are more resilient, more flexible, and more aligned with regulatory expectations.

Issuing in the next era

When asked about the next five to ten years, Indupuri cautioned against long-range predictions, but acknowledged that AI is accelerating faster than the industry has ever seen.

“What used to take a decade is now happening in a year,” he said. “Innovation cycles have been compressed significantly.”

When focusing on select processes such as drug discovery, virtual cell models and advanced generative design tools have already began reshaping early-stage research, accelerating identification of promising compounds.

In development, AI is poised to operate across the entire data continuum, from ingestion to insight to submission.

The compression of time and the expansion of capability, Indupuri argues, will allow companies to pursue more ambitious R&D programs, and take “more shots on goal,” while bringing therapies to patients at a faster rate than previously possible.

Matovski echoed this optimism but also emphasized that responsible frameworks must remain front-and-center, ensuring both patient safety and regulatory alignment as AI becomes omnipresent.

AI’s connective layer across the value chain

As AI is further implemented into enterprise operations, Matovski noted that digital workers are designed to operate “within a governed system of work that tracks every action line by line,” enabling insights to move seamlessly from clinical to safety to regulatory without losing traceability. That transparency, he said, is what transforms AI from an isolated analytic tool into an auditable, cross-functional engine.

Similarly, Indupuri also touched on the need for integrated architectures, saying that embedding AI into existing deterministic workflows is essential for adoption at scale.

These perspectives point to a future where AI functions as the bridge between pharmaceutical ecosystems, ensuring continuity, reducing friction, and enabling decisions to flow across functions seamlessly.

A sector on the brink of transformation

As AI continues to embed itself across the pharmaceutical value chain, the industry stands at a pivotal defining moment. As transparency, governance, and strong data foundations emerge as the non-negotiable building blocks of responsible adoption, at the same time, the operational pressures of growing data volume, increasingly complex trial designs, and rising development costs are drive unprecedented demand for automation and real-time insight.

If industry leaders can balance innovation with oversight, the next era of AI can promise the following:

• Shorter cycle times
• Reduced risk
• Accelerated decision-making
• Enhanced compliance
• More flexible and adaptive trials
• Improved patient outcomes

AI’s emergence is poised to redefine the architecture of pharmaceutical research and development, and as the leaders guiding these technologies emphasize, the stakes, and the opportunities, could not be higher.